Early and specific targeted mass spectrometry-based identification of bacteria in endotracheal aspirates of patients suspected with ventilator-associated pneumonia

Abstract

Rapid and reliable pathogen identification is compulsory to confirm ventilator-associated pneumonia (VAP) in order to initiate appropriate antibiotic treatment. In the present proof of concept, the effectiveness of rapid microorganism identification with a targeted bottom-up proteomics approach was investigated in endotracheal aspirate (ETA) samples of VAP patients. To do so, a prototype selected-reaction monitoring (SRM)-based assay was developed on a triple quadrupole mass spectrometer tracking proteotypic peptide surrogates of bacterial proteomes. Through the concurrent monitoring of 97 species-specific peptides, this preliminary assay was dimensioned to characterize the occurrence of six most frequent bacterial species responsible for over more than 65% of VAP. Assay performance was subsequently evaluated by analyzing early and regular 37 ETA samples collected from 15 patients. Twenty-five samples were above the significant threshold of 10⁵ CFU/mL and five samples showed mixed infections (both pathogens ≥ 10⁵ CFU/mL). The targeted proteomics assay showed 100% specificity for Acinetobacter baumannii, Escherichia coli, Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. No false bacterial identification was reported and no interference was detected arising from the commensal flora. The overall species identification sensitivity was 19/25 (76%) and was higher at the patient level (84.6%). This successful proof of concept provides a rational to broaden the panel of bacteria for further clinical evaluation.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10096-020-04132-y.

Introduction

Ventilator-associated pneumonia (VAP) is the most frequent health care-associated infection in critically ill patients and is associated with a significant mortality and morbidity [1]. So far, clinicians empirically treat the patients based on guidelines [2] and on the epidemiology of the intensive care unit (ICU). Without early microbiological identification, the treatment includes usually large broad-spectrum antibiotic, increasing the risk of multidrug-resistant bacteria (MDR) selection [3]. The early identification of the causative pathogen is thus crucial for the management of the patient. Indeed, an early targeted and appropriate antibiotic therapy is correlated with the reduction of mechanical ventilation duration, ICU length stay, and hospitalization costs [4].

Besides rapid molecular methods developed recently, semi-quantitative cultures of lower respiratory tract samples (bronchoalveolar lavage (BAL), protected specimen brush (PSB), or endotracheal aspirates (ETA)) remain routinely used for therapeutic decision and less costly. However, semi-quantitative cultures are difficult to standardize and delay the microbial identification for at least 18–24 h. Although controverted [5–7], ETA, which are non-invasive specimens, have been proposed for both pre-infection monitoring and VAP diagnosis [8].

Various etiologic pathogens are involved in VAP, including Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Acinetobacter baumannii, and Enterobacteriaceae covering almost 80% of the cases with little epidemiological modification overtime [2, 9].

With regards to pathogen identification, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) undoubtedly represents a real revolution in that it has drastically shortened the delay of the identification and resistance characterization step, even if a prior culture if usually still required, for MS sensitivity issues. Furthermore, MALDI-TOF-MS-based identification fails when considering a complex, faintly multicontaminated biological matrix [10] and, as a result, is not compatible with direct bacterial identification in ETA samples. As an alternative, recent studies illustrated the value of targeted bottom-up proteomics approaches for bacteria characterization after trypsin digestion of the extracted whole proteome [11]. Developed on low- or high-resolution mass spectrometers, they relied on the monitoring of well-selected peptide panels for, e.g., the detection of four bacteria involved in respiratory tract infections [12], the concomitant identification, resistance and virulence characterization of S. aureus in positive blood cultures [13], and the deciphering of resistance mechanisms [11–17].

In this proof of concept, a targeted multiplex assay was developed and implemented for assessing the effectiveness of targeted MS in identifying a panel of six microorganisms predominantly associated with VAP directly from ETA samples without culture.

Materials and methods

Reagents and chemicals

LC-MS grade acetonitrile and water, formic acid (FA), dithiothreitol (DTT), iodoacetamide (IAA), ammonium bicarbonate, and porcine trypsin were purchased from Sigma-Aldrich-Fluka (Lyon, France). Blood culture bottles and agar plates for bacterial culture were obtained from bioMérieux (Marcy L’Etoile, France).

Bacterial strains

In this preliminary proof of concept, a VAP diagnosis assay (VAP-6) was developed to detect the six bacterial species most frequently detected in VAP, i.e., A. baumannii, Escherichia coli, H. influenzae, P. aeruginosa, S. aureus, and S. pneumoniae. In order to assess the specificity of the peptide panel of VAP-6 SRM assay, shotgun proteomics experiments were also carried out on 36 other species used as negative controls. Among these 36 species, 6 species represented less frequent bacteria that could be involved in respiratory tract infection (Enterobacter aerogenes, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, and Serratia marcescens), 22 species were from the commensal oro-pharyngeal flora, often identified in respiratory samples (Haemophilus (H. haemolyticus, H. parainfluenzae), Neisseria (N. sicca, N. subflava), Staphylococcus (S. epidermidis, S. hominis, S. haemolyticus, S. saprophyticus, S. simulans, S. warneri), Streptococcus (S. agalactiae, S. anginosus, S. constellatus, S. infantis, S. intermedius, S. mitis, S. mutans, S. oralis, S. pseudopneumoniae, S. pyogenes, S. salivarius, S. sanguinis), and the remaining eight species were phylogenetically closely related to the pathogens (Acinetobacter (A. calcoaceticus, A. haemolyticus, A. junii), Pseudomonas (P. alcaligenes, P. putida, P. stutzeri), Morganella morganii, and Serratia fonticola). The bacterial strains used in this study came from the bioMérieux collection (Supplementary data Table 1).

ETA samples and microbiological analysis

A prospective sample collection was conducted in the ICU of Limoges University Hospital (France) to obtain 37 ETA specimens from 15 patients (> 18 years old) who had been under mechanical ventilation for at least 48 h and who were suspected of VAP.

For each ETA, an aliquot was frozen at − 80 °C for further proteomic analysis (see below ETA sample preparation) and one aliquot was used for a cultivation-dependent analysis performed in the microbiology laboratory of the Limoges University hospital according to the recommendations of the European Society for Clinical Microbiology and Infectious Diseases society (ESCMID) [18]. Bacterial identification was performed with the VITEK® MS (bioMérieux) and antibiotic susceptibility testing was performed for bacteria considered as pathogens with the VITEK® 2 system (bioMérieux).

Informed consent for inclusion in the study was obtained from an authority member of the family. A non-opposition certificate was transmitted to the patient. The data conservation and the experimental protocol were conducted according to national regulations and approved by national ethical committee CCTIRS (French Consultative Committee of Information Treatment concerning health Research) (File no 12.001) and the CNIL (National commission of Informatics and freedom) (file no EGY/VCS/AR125816).

Strain preparation

One milliliter of bacterial inoculum at 4 McF was centrifuged at 6000g during 10 min. The pellet was suspended into 150 μL of 5 mM DTT, 50 mM ammonium bicarbonate buffer, pH 8.0. Bacterial lysis was accomplished in 5 min using ultrasound (Microlab ID STARlet, Hamilton Robotics, Reno, NV, USA) with beads from Biospec Product (Bartlesville, OK, USA), followed by alkylation in 12.5 mM IAA during 5 min in the dark. Protein digestion was then carried out using trypsin (50 μL at 1 mg/mL) during 15 min at 50 °C. The enzyme activity was stopped by the addition of 0.05% FA.

ETA sample preparation

ETA samples were fluidized by the addition of 20 U/mL DNase (Promega, Madison, WI, USA) followed by incubation for 15 min at room temperature. For a complete fluidification, samples were further half-diluted in Digester (Eurobio, les Ulis, France) for 15 min at room temperature. Saponin was used for differential lysis between human cells and bacteria [19]; then, the bacterial cells were sedimented by centrifugation at 12,000g during 10 min.

The pellet was suspended in 700 μL of 5 mM DTT, 50 mM ammonium bicarbonate buffer, pH 8.0. Bacterial lysis and digestion were performed as described above for the reference strains. Lysed and digested samples were desalted using a solid-phase extraction (SPE) OASIS® HLB cartridge (Waters, Milford, MA, USA) into the RapidTrace SPE workstation (Biotage, Uppsala, Sweden) according to manufacturer instructions. The eluted sample was dried using a TurboVap (Biotage) and suspended in 200 μL of 0.05% FA containing water. The sample preparation time was 2 h per sample batch (16 samples).

LC-ESI-Q-TOF-MS analysis for the specific peptide discovery phase

Screening for strain-specific peptide identification was performed in Data Dependent Analysis (DDA) mode using a LC Ultimate 3000 chromatography system (Dionex, Sunnyvale, CA, USA) hyphenated to a TripleTOF®5600 MS (Sciex, Framingham, MA, USA). Mobile phase A was water with 0.1% FA, and mobile phase B was acetonitrile with 0.1% FA. The gradient ranged from 2 to 37% of B in 60 min at 300 μL/min. A MS/MS fragmentation spectrum was registered during 75 ms for all precursor ions detected above 200 counts in the survey MS spectrum (250 ms), with a dynamic exclusion time of 3 s. MS control and data acquisitions were performed using Analyst 1.6 software (Sciex).

Data analysis for the specific peptide discovery phase

Spectra analysis and database interrogations were made with ProteinPilot™ software 4.0.8085 (Sciex). Peptides were identified using the rapid identification mode and a confidence score (ProtScore) superior to 95%. Carbamidomethylation was considered as a fixed chemical modification and only one missed cleavage was allowed. The databases used were UniProtKB/Swiss-Prot and UniProtKB/TrEMBL. Databases were restricted at different taxonomic levels depending on the species. The family level was used for Enterobacter spp., Morganella spp., Serratia spp. (Enterobacteriaceae), Neisseria spp. (Neisseriaceae), Haemophilus spp. (Pasteurellaceae), Pseudomonas spp. (Pseudomonadaceae), Staphylococcus spp. (Staphylococcaceae), and Streptococcus spp. (Streptococcaceae); the genus level was used for Acinetobacter spp., Klebsiella spp., and Proteus spp.; the species level was retained for E. coli. Then, each peptide detected in a single species and in at least 70% of the strains of this specie has been validated as specific and inclusive. Moreover, an identity BLAST alignment [20] was made on the two databases previously cited to confirm in silico the species specificity of the peptides.

SRM method construction

The SRM method was developed using a Nexera LC (Shimadzu) system hyphenated to a hybrid quadrupole linear ion trap mass spectrometer (QTRAP® 5500, Sciex) and Analyst 1.5.2 software. The SRM assays were created by selecting a subset of species-specific peptides among the best-flyer candidates identified during the discovery phase. Peptides containing amino acid residues prone to partial chemical modifications, such as methionine and cysteine, were not retained in the final list. The three most intense transitions were selected to build the SRM method. The peptides were separated on a C18 reversed phase column 2.1 × 100 mm, 3.5 μm, 130 Å (BEH, Waters Milford, MA, USA) in 28 min at 300 μL/min using a 2% to 37% of B gradient. Two columns were used in parallel for increased throughput. The scheduled SRM method used 264 s time windows centered on the peptide retention times measured by spiking ETA samples with pure bacteria. Q1 and Q3 quadrupole resolutions were adjusted to unitary resolution. The SRM method (VAP-6 SRM assay) contained 291 transitions tracking 97 species-specific peptides used as surrogate targets of A. baumannii, E. coli, H. influenzae, P. aeruginosa, S. aureus, and S. pneumoniae (Supplementary Data Table 1).

Data analysis: peptide identification in ETA samples

Scheduled SRM data processing was performed using Multiquant 2.0 software (Sciex) and the integration algorithm Signal Finder. The software allows extracting a chromatogram corresponding to each peptide. Post process result interpretation was based on the chromatographic peak area. Peptide detection was considered positive if the three transitions per peptide were simultaneously detected with a standard deviation of the retention time lower than 0.03 s and a conserved ratio (± 20% deviation) between the three transition as established by analyzing the pure strains. Bacteria quantification in ETA was performed using integration of chromatographic peptide areas.

Results and discussion

Identification of species-specific peptides

The panel of peptides, selected in the VAP-targeted MS assay, was designed by combining shotgun proteomics experiments and a bioinformatics pipeline for selection and validation steps (Fig. 1). Fundamentally, two drastic criteria guided the final peptide choice: proteotypicity and high ionization yield. They were assessed using protein extracts of the six species most frequently associated to VAP (A. baumannii, E. coli, H. influenzae, P. aeruginosa, S. aureus, and S. pneumoniae) and 36 “control” species (Table 1).

Fig. 1.

Discovery process for selecting species-specific peptide targets. Protein identifications were performed with a LC-ESI-Q-TOF. *Peptide specificity was verified experimentally by comparison using 194 bacterial strains including 115 different strains from 36 species considered as control species. Sensitivity was ensured by retaining only peptides present in more than 70% of the strains belonging to a species. **Peptide specificity was verified in silico using identity BLAST and UniProtKB database. The peptide selection was based on the intensity of the chromatographic peak of the peptide

Table 1.

Species-specific peptide identification and SRM method building

	Discovery phase		Validation phase			SRM method
			Experimental DDA analysis		In silico
	Number of strains used for peptide identification	Number of identified peptides	Number of strains used as negative control	Specific and inclusive peptidesa	Specific peptides against all Uniprot taxonomies (BLAST)	Number of targeted specific peptidesb
E. coli	29	14,107	93d	288	70c	24
A. baumannii	10	8049	104e	562	52	16
S. pneumoniae	7	7408	140f	85	44	11
P. aeruginosa	10	5999	121g	5397	304	20
H. influenzae	10	7456	122h	5321	520	10
S. aureus	13	6043	99i	1283	282	15

^aSpecificity was validated for peptides not identified in negative control strains; inclusiveness was validated for peptides identified in 70% of the targeted strains

^bInteresting peptides were selected among the specific one (previous column), regarding their amino-acid sequence and MS sensitivity

^cE. coli or Shigella-specific peptides

^dA. baumannii, E. aerogenes, E. cloacae, H. influenzae, K. oxytoca, K. pneumoniae, P. mirabilis, P. aeruginosa, S. marcescens, S. aureus, S. pneumoniae

^eA. calcoaceticus, A. haemolyticus, A. junii, E. aerogenes, E. cloacae, E. coli, H. influenzae, K. oxytocca, K. pneumoniae, P. mirabilis, P. aeruginosa, S. marcescens, S. aureus, S. pneumoniae

^fA. baumannii, E. cloacae, E. aerogenes, E. coli, H. influenzae, K. oxytoca, K. pneumoniae, P. mirabilis, P. aeruginosa, S. marcescens, S. aureus, S. agalactiae, S. anginosus, S. constellatus, S. infantis, S. intermedius, S. mitis, S. mutans, S. oralis, S. pseudopneumoniae, S. pyogenes, S. salivarius, S. sanguinis

^gA. baumannii, E. cloacae, E. aerogenes, E. coli, H. influenzae, K. oxytoca, K. pneumoniae, P. mirabilis, P. alcaligenes, P. putida, P. stutzeri, S. marcescens, S. aureus, S. pneumoniae

^hA. baumannii, E. cloacae, E. aerogenes, E. coli, H. haemolyticus, H. parainfluenzae, K. pneumoniae, K. oxytoca, P. mirabilis, P. aeruginosa, S. marcescens, S. aureus, S. pneumoniae

ⁱA. baumannii, E. cloacae, E. aerogenes, E. coli, H. influenzae, K. oxytoca, K. pneumoniae, P. mirabilis, P. aeruginosa, S. marcescens, S. haemolyticus, S. warneri, S. epidermidis, S. pneumoniae

In total, 49,062 tryptic peptides were identified during the proteomics discovery phase after having analyzed strains of reference and representative of the diversity of each of the VAP-6 species (Table 1). A shotgun proteomics strategy was similarly deployed on the 115 bacterial strains from 36 species considered as a control panel (Supplementary data Table 1). This discovery step enables to extract a list of peptides specifically detected in the VAP-6 panel and considered as “best flyer” candidates. However, curated public databases are not yet comprehensive for all bacterial species. For instance, H. influenzae displays only 3090 and 51,400 entries in Swiss-Prot and in TrEMBL databases, respectively, while E. coli exhibits 23,139 and 1,671,579 entries (www.uniprot.org, 2020, April the 8th).

Moreover, different strains of the same species can exhibit an important genomic diversity, i.e., E. coli has only 50% of highly conserved genes among strains [21]. Genes can also be transferred between strains among the same or different species. Consequently, the reliable selection of species-specific peptides should not exclusively rely on protein database mining but requires, in contrast, thorough validation across the analysis of multiple species and of different strains of the same species. As a typical example of such a mandatory extensive validation procedure, the IIELAGHLDTYIPEPERK tryptic peptide arising from K. pneumoniae (Elongation factor Tu) was predicted absent in S. pneumoniae proteome using UniProtKB, while it was experimentally detected (Fig. 2). Last but not least, encoded proteins can exhibit significant differential expression level between clinical isolates, which in turn may induce false-negative detection whether the peptide signals fall below the lower limit of detection.

Fig. 2.

Extracted SRM chromatogram signals of IIELAGHLDTYIPEPERK peptide from K. pneumoniae and S. pneumoniae species (transitions: 698.71/868.49; 698.71/1031.55; 698.71/1132.60). a Chromatogram of a pure K. pneumoniae digest (API 9103130 strain), peptide retention time: 21.47 min. b Chromatogram of a pure S. pneumoniae digest (ATCC 49619 strain), peptide retention time: 21.59 min. IIELAGHLDTYIPEPERK peptide showed a BLAST identity to K. pneumoniae elongation factor protein A6TEX7 (UniProtKB accession number). It also has been described in Erwinia tracheiphila, Leminorella grimontii, and Serratia ficaria. However, the same peptide was not yet described in S. pneumoniae while it was clearly detected experimentally in b

Hence, we have applied a first selection filter consisting in choosing only the peptides identified during the proteomics experiments in at least 70% of the VAP-6 bacteria and not retrieved in the control panel. Then, their specificity was confirmed by a BLAST query against UniProtKB (Swiss-Prot and TrEMBLE) public databases, which led to characterize from 44 up to 520 species-specific peptides depending on the species (Table 1). As anticipated, no peptide was identified as being strictly proteotypic of E. coli due to close genetic background with the intestinal Shigella genus [22]. However, it is not a hurdle since the Shigella genus is not retrieved in a VAP infection context.

The last step of building the VAP-6 SRM method followed three rules so as to warrant the assay as reliable and sensitive as expected: (i) the peptide panel had to be dispersed throughout the chromatogram in order to limit the number of transitions concurrently monitored within the same scheduled window of retention time; (ii) for each species, the peptides were selected in the BLAST-specific list among those harboring the highest signal to noise ratio at the precursor ion level; (iii) with very few exceptions, peptides harboring a proline or a histidine close to the N terminus were excluded of the selection in order to favor the fragmentation pathway leading to y type fragment ions with close intensity. Ninety-seven peptides (11 to 24 signature peptides per species) were thus ultimately retained in the VAP-6 SRM method. The intrinsic sensitivity of the assay was assessed by monitoring all transitions in a diluted series of trypsin digests of pooled individual cultures of VAP-6 panel. All bacteria were successfully identified (Fig. 3) with a limit of detection (LOD) ranging from 10⁵ to 10⁶ CFU/mL depending on the species (Supplementary data Fig. 1). These detection limits were consistent with the specifications required for true clinical sample analysis considering a VAP pathogenicity threshold at 10⁵ CFU/mL for ETA samples in the European and American guidelines [18, 23].

Fig. 3.

Multiplex capability of the VAP-6-SRM method. 10⁸ CFU of each six species pooled (A. baumannii, E. coli, H. influenzae, P. aeruginosa, S. aureus, S. pneumoniae) were injected in a LC-ESI-QqQ-MS system and followed simultaneously in one unique run (28 min) using the VAP-6-SRM method. This figure shows the reconstituted chromatogram of the extraction of three specific peptides per species. *¹A. baumannii SGTTGNIEAATK: (B7GW18 UniProtKB accession number; retention time: 9.8 min); NIGLLAGLPK (A0A059ZM33 UniProtKB accession number; retention time: 20.44 min); GQAINVQNIYGK (D0C807 UniProtKB accession number; retention time: 15.56 min). *²E. coli VVAVGDQVEK: (P75691 UniProtKB accession number; retention time: 11.24 min); DYVEGETAAK (P0A9Q7 UniProtKB accession number; retention time: 9.76 min); WNGVTVTPK (P0ADU5 UniProtKB accession number; retention time: 13.99 min). *³H. influenzae: YAYVTLGNK (P43839 UniProtKB accession number; retention time: 14.71 min); VQFEVLHSDK (A0A0D0IG76 UniProtKB accession number; retention time: 14.9 min); DSSAEFDNSK (P44076 UniProtKB accession number; retention time: 8.73 min). *⁴P. aeruginosa: TALATAVAAGTR (Q8KQ36 UniProtKB accession number; retention time: 13.7 min); NIAIAAGDSAK (P72151 UniProtKB accession number; retention time: 11.9 min); VSEGLVLAEPAK (Q8KQ36 UniProtKB accession number; retention time: 15.96 min). *⁵S. aureus: AFAQLVTK (Q2FXQ1 UniProtKB accession number; retention time: 14.99 min); TQVVDTVAK (P80544 UniProtKB accession number; retention time: 10.7 min); VTDADFDSK (Q2FHT6 UniProtKB accession number; retention time: 10.45 min). *⁶S. pneumoniae: DLEVTTVVR (A0A0D6J7I5 UniProtKB accession number; retention time: 16.11 min); IDELDAEIAK (A0A0D6J7I5 UniProtKB accession number; retention time: 15.3 min); EVDDTIAEEK (A0A062WP99 UniProtKB accession number; retention time: 11.11 min)

Method validation using ETA samples

In order to assess the diagnostic value of the newly developed SRM-based proteomics assay, 37 ETA samples were successively collected from 15 patients suspected of VAP, then submitted in parallel to both the conventional cultivation-dependent approach and the direct VAP-6 SRM assay. Using the cultivation-dependent approach, at least one bacterial species was isolated in all the samples and significant clinical thresholds (≥ 10⁵ CFU/mL) were detected for 24 samples collected from 14 patients (Table 2). Five out of the six species targeted with the VAP-6-SRM assay were isolated (E. coli, H. influenzae, P. aeruginosa, S. aureus, and S. pneumoniae) and seven samples contained both of these species (Table 2). A. baumannii was not isolated in any of the cohort samples. Moreover, 29 out of the 37 samples showed growth of other bacterial species, mainly with a oro-pharyngeal flora origin. Despite of the molecular complexity of ETA matrix sample and univocal contaminations by oro-pharyngeal bacteria, as highlighted by the cultivation-dependent assay, the VAP-6 SRM assay exhibits 100% specificity (no false bacterial identification) for E. coli, H. influenzae, P. aeruginosa, S. aureus, and S. pneumoniae (Table 3). This performance features the relevancy of the strategy deployed for selecting the peptide candidates in the present VAP-6 assay, which could be replicated for other species to expand the SRM-based VAP assay.

Table 2.

Bacterial species and bacterial quantities (established by semi-quantitative culture) in clinical ETA samples and species identification by LC-ESI-QqQ-MS in SRM mode

Patient	Sample	Sampling daya	Identified pathogen using VITEK® 2	Pathogen quantity (CFU/mL)	Others identified bacteria (via VITEK® 2) and quantity (CFU/mL)	Pathogen identified using LC-ESI-QqQ-MS in SRM mode
1	1_1	Day 1	E. coli	104		E. coli
	1_2	Day 1	E. coli	> 106	S. constellatus (105) S. haemolyticus (> 106)	E. coli
	1_3	Day 2	E. coli	106	S. constellatus (104) S. haemolyticus (106)	E. coli
	1_4	Day 3	E. coli	> 106	S. constellatus (103) S. haemolyticus (104)	E. coli
	1_5	Day 4	E. coli	106	S. haemolyticus (103)	E. coli
	1_6	Day 5	E. coli	105		E. coli
	1_7	Day 6	E. coli	5.105	P. vulgaris (103)	E. coli
	1_8	Day 7	E. coli	103	P. vulgaris (104) S. constellatus (103) Aggregatibacter spp. (105) S. haemolyticus (105)	No
2	2_1	Day 1	S. aureus	104	S. viridans (104) C. pseudodiphteritium (105) Corynebacterium sp > 105	No
	2_2	Day 2	S. aureus	106	C. pseudodiphteritium (106) Corynebacterium sp (> 106)	S. aureus
	2_3	Day 2	S. aureus	105		S. aureus
	2_4	Day 3	S. aureus	103	E. faecalis (103) S. epidermidis (106) S. viridians (104) Corynebacterium sp (103)	No
	2_5	Day 4	P. aeruginosa	104	E. faecalis (103) S. epidermidis (103)	No
3	3_1	Day 1	S. aureus	106	S. constellatus (> 106) S. viridans (103) H. parainfluenzae (105) Neisseria spp. (105)	S. aureus
	3_2	Day 2	S. aureus	105	H. parainfluenzae (103) S. constellatus (105)	No
	3_3	Day 3	S. aureus	105		S. aureus
4	4_1	Day 1	S. aureus	104	Neisseria spp. (105) R. mucilaginosus (104) H. haemolyticus (105) Non hemolytic Streptococci (105)	No
	4_2	Day 2	S. aureus	106	S. viridans (103)	S. aureus
5	5_1	Day 1	S. aureus	105	E. faecalis (105) C. striatum (104) S. epidermidis (104)	S. aureus
	5_2	Day 3	S. aureus	104	C. striatum (104) E. faecalis (104) S. viridians (103)	S. aureus
	5_3	Day 4	S. aureus	104	Aspergillus spp. (103) Lactobacillus spp. (104) Corynebacterium sp (104)	S. aureus
6	6_1	Day 1	S. aureus	104	Corynebacterium sp (> 106) H. parainfluenzae (103) S. viridans (104)	No
7	7_1	Day 1	S. aureus	105	S. viridans (105)	S. aureus
8	8–1	Day 1	S. aureus	106	Coagulase negative Staphylococcus (103) S. viridans (106) Aggregatibacter spp. (106) Neisseria spp. (105)	No
	8–2	Day 3	S. aureus	106	Neisseria spp. (103)	S. aureus
9	9_1	Day 1	S. aureus	106	E. cloacae (> 106)	No
	9_2	Day 3	S. aureus	102b	E. faecalis (> 106) E. cloacae (> 106)	S. aureus
	9_3	Day 4	S. aureus	105	E. faecalis (102) E. cloacae (105)	S. aureus
10	10_1	Day 1	H. influenzae	> 106		No
			S. pneumoniae	> 106		No
	10_2	Day 2	H. influenzae	> 106		H. influenzae
			S. pneumoniae	> 106		No
11	11_1	Day 1	H. influenzae	106	S. viridians (> 106) R. mucilaginous (104) Neisseria spp. (104) Aggregatibacter spp. (104)	H. influenzae
			S. pneumoniae	106		S. pneumoniae
	11_2	Day 2	H. influenzae	105	S. aureus (103) S. viridans (106) Coagulase negative Staphylococcus (104) H. parainfluenzae (105) Neisseria spp. (103)	No
			S. pneumoniae	106		S. pneumoniae
12	12_1	Day 1	H. influenzae	106		H. influenzae
			S. pneumoniae	104		No
	12_2	Day 2	H. influenzae	106		H. influenzae
			S. pneumoniae	> 106		S. pneumoniae
13	13–1	Day 1	E. coli	104	H. alvei (103) P. vulgaris (103)	No
			S. pneumoniae	> 106		S. pneumoniae
14	14_1	Day 1	P. aeruginosa	104	S. epidermidis (103) Yeast (103)	No
15	15_1	Day 1	P. aeruginosa	104	Coagulase negative Staphylococcus (104)	No

^aDepending on patient sputum production, ETA sampling was not possible each day

^bProbable error in quantitative culture. The patient sampling made before and after sample 9–2 (sample 9–1 and 9–3), harbor S. aureus with a bacterial load ≥ 10⁵ CFU/mL

Table 3.

Performance of bacterial identification by ESI-LC-QqQ-MS in ETA samples (semi-quantitative culture and VITEK® 2 identification as references)

		Pathogen ≥ 105 CFU/mL identified by MS
Pathogen in ETA	Pathogen false identification (specificity)	In ETA case number (sensitivity)	In patient case number (sensitivity)
E. coli	0/37 (100%)	6/6 (100%)	1/1 (100%)
S. aureus	0/37 (100%)	9/12 (75%)	8/8 (100%)
S. pneumoniae	0/37 (100%)	4/6 (66.7%)	4/5 (80%)
H. influenzae	0/37 (100%)	4/6 (66.7%)	4/5 (80%)
P. aeruginosaa	0/37 (100%)	-	-
H. influenzae and S. pneumoniae	0/37 (100%)	At least 1 pathogen: 4/5 (80%) All the pathogens: 2/5 (40%)	At least 1 pathogen: 4/4 (100%) All the pathogens: 2/4 (50%)
Total	0/37 (100%)	At least 1 pathogen: 21/25 (84%) All the pathogens: 19/25 (76%)	At least 1 pathogen: 13/13 (100%) All the pathogens: 11/13 (84.6%)

^aThe three samples harboring P. aeruginosa were quantified at 10⁴ CFU/mL by semi-quantitative culture

Microorganisms present at the significant clinical threshold ≥ 10⁵ CFU/mL were identified by SRM in 21 out of 25 ETA samples containing at least one pathogen (84% averaged sensitivity) (Tables 2 and 3). Seven ETA samples, from patients 10 to 14, harbored two of the 6 targeted pathogens (6× H. influenzae/S. pneumoniae and 1× E. coli/S. pneumoniae) with CFU/mL ranging from 10⁴ to 10⁶. Both species were detected by SRM in two ETA samples (samples 11_1 and 12_2), one microorganism out two was detected in four other cases (samples 10_2, 11_2, 12_1, and 13_1) while no microorganism was identified in one case (sample 10_1) despite CFU/mL ≥ 10⁵ for both. Finally, three samples (3_2, 8_1, 9_1) were declared negative following the VAP-6 proteomics assay while they were detected positive at ≥ 10⁵ CFU/mL with the cultivation-dependent approach. Three of them grew only one species (S. aureus) and one was polymicrobial with H. influenzae and S. pneumoniae.

The overall sensitivity of SRM-based species identification was 19/25 (76%) for ETA samples (Table 3), 6/6 (100%), 4/6 (66.7%), 9/12 (75%), and 4/6 (66.7%) for E. coli, H. influenzae, S. aureus, and S. pneumoniae, respectively. The sensitivity was higher at the patient level (84.6%) and species were correctly identified in 1/1 (100%), 4/5 (80%), 8/8 (100%), and 4/5 (80%) patients, respectively.

Among the 11 samples showing a bacterial load around 10⁴ CFU/mL, only 3 (27.3%) lead to species identification by the VAP-6 assay. This latter observation challenges the SRM use in clinics for early VAP diagnosis when the bacterial load is low. Further refinement in the sample preparation step may improve the LOD as well as the diagnosis robustness, particularly during the liquefaction step and the separation of bacteria from human cells. Indeed, we noticed that the false-negative identification for some ETA samples correlated with their difficulty to be processed. Our observation of variability in the physico-chemical properties of ETA samples may explain the lack of identification in sample 10_1 and in monoinfected 3_2, 8_1, and 9_1 samples, despite a CFU/mL value estimated from pure cultures well beyond the SRM LOD. The variability of the physico-chemical properties of ETA matrix between patients can impact the sample preparation, the trypsin digestion yield, and consequently the success of identification. The second cause of missed identification at a bacterial load of around 10⁵ CFU/mL may be attributed to the greatest resistance of Gram-positive bacteria towards trypsin digestion since five out of the seven missed identifications were ETA harboring either S. aureus or S. pneumoniae. As stated above, this observation is an incentive for further improvement of sample preparation parameters.

Another and even more obvious option for improving the LOD is simply moving to a more recent mass spectrometer generation and to microflow format [24]. Interestingly, many mass spectrometer manufacturers already propose In Vitro Diagnostics-labeled MS platforms based on liquid chromatography coupled to a triple quadrupole instrument, which underline their interest for clinical diagnosis and suggest continued progress both in terms of instrument and software. Interestingly, quantitation using SRM and cultivation-dependent analysis were in agreement during patient monitoring (Fig. 4).

Fig. 4.

Patient monitoring by SRM and quantitative culture analysis. ETA samples from one patient, infected by E. coli, were obtained from day 1 to day 8. The semi-quantitative cultures are referred on the vertical left axis and represented by vertical bars. The integration area of a SRM chromatographic peak from an E. coli peptide is referred on the vertical right axis and represented by a black line

In conclusion, SRM-based assay could be an effective and non-invasive way to regularly monitor VAP by identifying mixed pathogens on a reduced 4 h time scale from ETA samples. Depending on the species, the LODs achieved with the assay in ETA samples range from 10⁴ CFU/mL to 10⁶ CFU/mL, with 76% of sensitivity for a clinical threshold value of 10⁵ CFU/mL. These results provide an incentive to expand the pathogen panel and to move on a more sensitive chromatographic format for next performing extensive clinical evaluation of VAP diagnosis based on targeted MS with regard with the standard of care.

Authors’ contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Chloé Bardet, Olivier Barraud, Marc Clavel, Tanguy Fortin, Jean-Philippe Charrier, Bruno François, Jérôme Lemoine, and Marie-Cécile Ploy. The first draft of the manuscript was written by Chloé Bardet, Jérôme Lemoine, and Marie-Cécile Ploy and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

C.B. was funded by the Association Nationale de la Recherche et de la Technologie (ANRT), grant No 2011/0456. This project was part of the Advanced Diagnostics for New Therapeutic approaches, a program dedicated to personalized medicine, coordinated by Mérieux Alliance and supported by the French public agency, OSEO.

Data availability

The data conservation and the experimental protocol were conducted according to national regulations and approved by national ethical committee CCTIRS (French Consultative Committee of Information Treatment concerning health Research) (File no 12.001) and the CNIL (National commission of Informatics and freedom) (file no EGY/VCS/AR125816).

Compliance with ethical standards

Conflict of interest

BF, OB, and MCP institutions have received funding from bioMérieux to run the VALIBI study. C.B., T.F., J.P.C., M.R., and J.Y.M. are, or were, employed by bioMérieux. C.B., T.F., and J.P.C. have filed patents assigned to bioMérieux.

Ethics approval

The data conservation and the experimental protocol were conducted according to national regulations and approved by national ethical committee CCTIRS (French Consultative Committee of Information Treatment concerning health Research) (File no 12.001) and the CNIL (National commission of Informatics and freedom) (file no EGY/VCS/AR125816).

Consent to participate

Informed consent for inclusion in the study was obtained from an authority member of the family. A non-opposition certificate was transmitted to the patient.

Consent for publication

Not applicable.

Code availability

Not applicable.